AACR 2024 – BioNTech sees pancreatic promise amid neoantigen delays
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
AACR 2024 preview – Lag3, TIGIT and more
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
AACR 2024 preview – clinical highlights and lowlights
The 2024 AACR abstract title drop features several noteworthy clinical studies.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
ASCO-GU – Corbus throws its hat into the Nectin-4 ring
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
ASCO-GU – Keytruda strengthens its kidney cancer monopoly
Merck adds an overall survival benefit while Bristol sinks further.
